ELSEVIER

Atherosclerosis 130 (1997) 237–239

ATHEROSCLEROSIS

Author index

Volume 130 (1997)

Akishita, M., Y. Ouchi, H. Miyoshi, K. Kozaki, S. Inoue, M. Ishikawa, M. Eto, K. Toba, H. Orimo, Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells **130**, 1
Alhenc-Gelas, F., see Haberbosch, W. **130**, 203
Andreeva, E.R., I.M. Pugach, A.N. Orekhov, Collagen-synthesizing cells in initial and advanced atherosclerotic lesions of human aorta **130**, 133
Ånggård, E., see Rutherford, C. **130**, 45
Aoki, K., see Hoshida, S. **130**, 53
Aoyama, Y., see Okubo, M. **130**, 153

Bausserman, L.L., see Zmuda, J.M. **130**, 199
Bertolini, S., G. Bittolo Bon, L.M. Campbell, M. Farnier, J. Langan, G. Mahla, P. Pauciullo, C. Sirtori, F. Egros, R. Fayyad, J.W. Nawrocki, Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia **130**, 191
Betteridge, D.J., see Smith, C.C.T. **130**, 87
Bittolo Bon, G., see Bertolini, S. **130**, 191
Bohle, R.M., see Haberbosch, W. **130**, 203
Bonora, E., see Willeit, J. **130**, 183
Braun-Dullaeus, R., see Haberbosch, W. **130**, 203
Breithardt, G., see Völker, W. **130**, 29
Buddecke, E., see Völker, W. **130**, 29

Campbell, L.M., see Bertolini, S. **130**, 191
Carrier, M., see Rutherford, C. **130**, 45
Catapano, A.L., see Ooyen, C. **130**, 143
Crisby, M., B. Kallin, J. Thyberg, B. Zhivotovsky, S. Orrenius, V. Kostulas, J. Nilsson, Cell death in human atherosclerotic plaques involves both oncosis and apoptosis **130**, 17

Danilov, S., see Haberbosch, W. **130**, 203
Dart, A., B. Sherrard, H. Simpson, Influence of apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease **130**, 161
Dorszewski, A., see Völker, W. **130**, 29
Düsing, R., see Seewald, S. **130**, 121

Egger, G., see Willeit, J. **130**, 183
Egros, F., see Bertolini, S. **130**, 191
Epping, P., see Seewald, S. **130**, 121
Eto, M., see Akishita, M. **130**, 1

Farnier, M., see Bertolini, S. **130**, 191
Fayyad, R., see Bertolini, S. **130**, 191
Fehringer, P., see Rothe, G. **130**, 215
Ferns, G., see Rutherford, C. **130**, 45
Franke, F.E., see Haberbosch, W. **130**, 203
Fukuda, K., see Watanabe, S. **130**, 101

Gardemann, A., see Haberbosch, W. **130**, 203
Gasche, C., see Rothe, G. **130**, 215
Gray, R.P., A. Panahloo, V. Mohamed-Ali, D.L.H. Patterson, J.S. Yudkin, Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction **130**, 171

Haberbosch, W., R.M. Bohle, F.E. Franke, S. Danilov, F. Alhenc-Gelas, R. Braun-Dullaeus, H. Hölschermann, W. Waas, H. Tillmanns, A. Gardemann, The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions **130**, 203
Handa, K., H. Ishii, S. Kono, K. Shinchi, K. Imanishi, H. Mihara, K. Tanaka, Behavioral correlates of plasma sex hormones and their relationships with plasma lipids and lipoproteins in Japanese men **130**, 37
Hasegawa, N., see Muramatsu, J. **130**, 179
Hasegawa, Y., see Okubo, M. **130**, 153
Hashimoto, H., see Umemura, K. **130**, 11
Höfling, B., see Nikol, S. **130**, 71
Hölschermann, H., see Haberbosch, W. **130**, 203

Hori, M., see Hoshida, S. **130**, 53
Hoshida, S., M. Nishida, N. Yamashita, J. Igarashi, K. Aoki, M. Hori, T. Kuzuya, M. Tada, Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril **130**, 53
Hozumi, T., see Kazumi, T. **130**, 93

Igarashi, J., see Hoshida, S. **130**, 53
Ihara, T., see Ishibashi, S. **130**, 113
Ikeda, U., see Ishibashi, S. **130**, 113
Ikeda, Y., see Sasaki, A. **130**, 109
Imanishi, K., see Handa, K. **130**, 37
Inoue, S., see Akishita, M. **130**, 1
Ishibashi, S., U. Ikeda, T. Ihara, K. Shimada, Tranilast inhibits contraction and Ca^{2+} movement of porcine coronary arteries **130**, 113
Ishida, Y., see Kazumi, T. **130**, 93
Ishii, H., see Handa, K. **130**, 37
Ishikawa, M., see Akishita, M. **130**, 1
Isner, J.M., see Nikol, S. **130**, 71
Itakura, H., see Sasaki, A. **130**, 109

Kaikkonen, J., see Nyyssönen, K. **130**, 223
Kallin, B., see Crisby, M. **130**, 17
Kanzaki, T., see Watanabe, S. **130**, 101
Kawaguchi, A., see Kazumi, T. **130**, 93
Kazumi, T., A. Kawaguchi, T. Hozumi, Y. Ishida, G. Yoshino, Serum HDL cholesterol values are associated with apoB-containing lipoprotein metabolism and triglyceride-body fat interrelation in young Japanese men **130**, 93
Kearney, M., see Nikol, S. **130**, 71
Kiechl, S., see Willeit, J. **130**, 183
Kobayashi, A., see Muramatsu, J. **130**, 179
Kondo, K., see Sasaki, A. **130**, 109
Kondo, K., see Umemura, K. **130**, 11
Kono, S., see Handa, K. **130**, 37
Kostulas, V., see Crisby, M. **130**, 17
Koyama, N., see Watanabe, S. **130**, 101
Ko, Y., see Seewald, S. **130**, 121
Kozaki, K., see Akishita, M. **130**, 1
Kurata, H., see Sasaki, A. **130**, 109
Kuzuya, T., see Hoshida, S. **130**, 53

Langan, J., see Bertolini, S. **130**, 191
Leclerc, G., see Nikol, S. **130**, 71

Maceroni, D., see Zmuda, J.M. **130**, 199
Mahla, G., see Bertolini, S. **130**, 191
Martin, W., see Rutherford, C. **130**, 45
Mihara, H., see Handa, K. **130**, 37
Miyoshi, H., see Akishita, M. **130**, 1
Mohamed-Ali, V., see Gray, R.P. **130**, 171
Morisaki, N., see Watanabe, S. **130**, 101
Muggeo, M., see Willeit, J. **130**, 183
Murakami, N., see Nikol, S. **130**, 71
Muramatsu, J., A. Kobayashi, N. Hasegawa, S. Yokouchi, Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin **130**, 179
Murase, T., see Okubo, M. **130**, 153

Nakashima, M., see Umemura, K. **130**, 11
Nawrocki, J.W., see Bertolini, S. **130**, 191
Newby, A.C., see Zaltsman, A.B. **130**, 61
Nikol, S., N. Murakami, J.G. Pickering, M. Kearney, G. Leclerc, B. Höfling, J.M. Isner, L. Weir, Differential expression of nonmuscle myosin II isoforms in human atherosclerotic plaque **130**, 71
Nilsson, J., see Crisby, M. **130**, 17
Nishida, M., see Hoshida, S. **130**, 53
Nyyssönen, K., E. Porkkala-Sarataho, J. Kaikkonen, J.T. Salonen, Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men **130**, 223

Oberhollenzer, F., see Willeit, J. **130**, 183
Oberhollenzer, M., see Willeit, J. **130**, 183
Okubo, M., Y. Hasegawa, Y. Aoyama, T. Murase, A G^{+1} to C mutation in a donor splice site of intron 2 in the apolipoprotein (apo) C-II gene in a patient with apo C-II deficiency: A possible interaction between apo C-II deficiency and apo E4 in a severely hypertriglyceridemic patient **130**, 153
Ooyen, C., A. Zecca, T. Zanelli, A.L. Catapano, Decreased intracellular degradation and increased secretion of apo B-100 in Hep G2 cells after inhibition of cholesteryl ester synthesis **130**, 143
Orekhov, A.N., see Andreeva, E.R. **130**, 133
Orimo, H., see Akishita, M. **130**, 1
Orrenius, S., see Crisby, M. **130**, 17
Ouchi, Y., see Akishita, M. **130**, 1

Panahloo, A., see Gray, R.P. **130**, 171
Patterson, D.L.H., see Gray, R.P. **130**, 171
Pauciullo, P., see Bertolini, S. **130**, 191
Pickering, J.G., see Nikol, S. **130**, 71
Poewe, W., see Willeit, J. **130**, 183
Porkkala-Sarataho, E., see Nyyssönen, K. **130**, 223
Pugach, I.M., see Andreeva, E.R. **130**, 133

Robenek, H., see Völker, W. **130**, 29
Rothe, G., J. Stöhr, P. Fehringer, C. Gasche, G. Schmitz, Altered mononuclear phagocyte differentiation associated with genetic defects of the lysosomal acid lipase **130**, 215
Rutherford, C., W. Martin, M. Salame, M. Carrier, E. Änggård, G. Ferns, Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor **130**, 45

Sachinidis, A., see Seewald, S. **130**, 121
Saito, Y., see Watanabe, S. **130**, 101
Sakamoto, Y., see Sasaki, A. **130**, 109
Salame, M., see Rutherford, C. **130**, 45
Salonen, J.T., see Nyyssönen, K. **130**, 223

Sasaki, A., K. Kondo, Y. Sakamoto, H. Kurata, H. Itakura, Y. Ikeda, Smoking cessation increases the resistance of low-density lipoprotein to oxidation **130**, 109
Schmitz, G., see Rothe, G. **130**, 215
Seewald, S., A. Sachinidis, R. Düsing, Y. Ko, C. Seul, P. Epping, H. Vetter, Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells **130**, 121
Seul, C., see Seewald, S. **130**, 121
Sherrard, B., see Dart, A. **130**, 161
Shimada, K., see Ishibashi, S. **130**, 113
Shinchi, K., see Handa, K. **130**, 37
Simpson, H., see Dart, A. **130**, 161
Sirtori, C., see Bertolini, S. **130**, 191
Smith, C.C.T., D.J. Betteridge, Reduced platelet serotonin content and release in familial hypercholesterolaemia **130**, 87
Stöhr, J., see Rothe, G. **130**, 215

Tada, M., see Hoshida, S. **130**, 53
Tanaka, K., see Handa, K. **130**, 37
Tezuka, M., see Watanabe, S. **130**, 101
Thompson, P.D., see Zmuda, J.M. **130**, 199
Thyberg, J., see Crisby, M. **130**, 17
Tillmanns, H., see Haberbosch, W. **130**, 203
Toba, K., see Akishita, M. **130**, 1

Ueda, S., see Watanabe, S. **130**, 101
Umemura, K., S. Watanabe, K. Kondo, H. Hashimoto, M. Nakashima, Inhibitory effect of prostaglandin E_1 on intimal thickening following photochemically induced endothelial injury in the rat femoral artery **130**, 11
Unruh, V., see Völker, W. **130**, 29

Vetter, H., see Seewald, S. **130**, 121
Völker, W., A. Dorszewski, V. Unruh, H. Robenek, G. Breithardt, E. Buddecke, Copper-induced inflammatory reactions of rat carotid arteries mimic restenosis/arteriosclerosis-like neointima formation **130**, 29

Waas, W., see Haberbosch, W. **130**, 203
Watanabe, S., N. Morisaki, M. Tezuka, K. Fukuda, S. Ueda, N. Koyama, K. Yokote, T. Kanzaki, S. Yoshida, Y. Saito, Cultured retinal pericytes stimulate in vitro angiogenesis of endothelial cells through secretion of a fibroblast growth factor-like molecule **130**, 101
Watanabe, S., see Umemura, K. **130**, 11
Weir, L., see Nikol, S. **130**, 71
Willeit, J., S. Kiechl, G. Egger, M. Oberhollenzer, F. Oberhollenzer, M. Muggeo, W. Poewe, E. Bonora, The role of insulin in age-related sex differences of cardiovascular risk profile and morbidity **130**, 183

Yamashita, N., see Hoshida, S. **130**, 53
Yokote, K., see Watanabe, S. **130**, 101
Yokouchi, S., see Muramatsu, J. **130**, 179
Yoshida, S., see Watanabe, S. **130**, 101
Yoshino, G., see Kazumi, T. **130**, 93
Yudkin, J.S., see Gray, R.P. **130**, 171

Zaltsman, A.B., A.C. Newby, Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity **130**, 61
Zanelli, T., see Ooyen, C. **130**, 143
Zecca, A., see Ooyen, C. **130**, 143
Zhivotovsky, B., see Crisby, M. **130**, 17
Zmuda, J.M., L.L. Bausserman, D. Maceroni, P.D. Thompson, The effect of supraphysiologic doses of testosterone on fasting total homocysteine levels in normal men **130**, 199

ELSEVIER

Atherosclerosis 130 (1997) 241–242

ATHEROSCLEROSIS

Subject index

Volume 130 (1997)

ACAT **130**, 143
ACAT inhibitors **130**, 143
ACE activity **130**, 53
ACE genotype **130**, 203
ACE phenotype **130**, 203
Ageing **130**, 183
Angiogenesis **130**, 101
Angiotensin II **130**, 53
Animal model **130**, 29
Antioxidant **130**, 223
Aorta **130**, 133
ApoAI **130**, 93
ApoB **130**, 93
ApoE **130**, 93
Apolipoprotein C-II **130**, 153
Apolipoprotein E **130**, 161
Apolipoprotein E4 **130**, 153
Apoptosis **130**, 17
Arteriosclerosis **130**, 29
Ascorbic acid **130**, 223
Atherectomy **130**, 71
Atherosclerosis **130**, 1, 17, 37, 53, 61, 71, 133
Atorvastatin **130**, 191

Basic fibroblast growth factor **130**, 101

Cell number **130**, 121
Cellularity **130**, 203
Cholesterol-lowering therapy **130**, 179
Cholesteryl ester storage disease **130**, 215
Copper-induced inflammation **130**, 29
Coronary heart disease **130**, 161
Cytosolic free calcium concentration **130**, 121

De-endothelialization **130**, 45
Diabetes **130**, 101
Differentiation **130**, 71
DNA synthesis **130**, 121
Donor splice site **130**, 153

Enalapril **130**, 53
Endothelial cells **130**, 101
Estrogen **130**, 1, 199
Exon skipping **130**, 153

Familial hypercholesterolaemia **130**, 87
Fibrotic plaques **130**, 203

Glucose **130**, 161

HDL cholesterol **130**, 93
Hemodynamics **130**, 179
Hepatocytes **130**, 143
High density lipoprotein **130**, 37
Histochemistry **130**, 29
HMG-CoA reductase inhibitor (pravastatin) **130**, 179
HMGRI **130**, 191
Homocysteine **130**, 199
Human **130**, 133
Hypercholesterolaemia **130**, 61
Hypercholesterolemia **130**, 191
Hypertriglyceridemia **130**, 153

Immunocytochemistry **130**, 133
Immunoglobulin **130**, 45
Insulin **130**, 183
Insulin sensitivity **130**, 171
Intimal smooth muscle cells **130**, 203
Intimal thickening **130**, 11

Lag time **130**, 109
LDL-C **130**, 191
Lipid synthesis **130**, 143
Lipoprotein oxidation **130**, 223
Low-density lipoprotein oxidation **130**, 109
Lysophosphatidic acid **130**, 121
Lysosomal acid lipase **130**, 215

Macrophages **130**, 29, 61
MAP kinase **130**, 121
Men **130**, 199
Menopause **130**, 183
Metabolic syndrome **130**, 183

Metalloproteinases **130**, 61
Migration **130**, 1
Monocyte subpopulations **130**, 215
Mononuclear phagocyte differentiation **130**, 215
Morphometry **130**, 29
Muscle contraction **130**, 113
Myocardial infarction **130**, 171

Na^+/H^+ antiport **130**, 121
NIDDM **130**, 171
Nonmuscle myosin **130**, 71

Oncosis **130**, 17

PAI-1 **130**, 171
Percent body fat **130**, 93
Pericytes **130**, 101
Peripheral circulation **130**, 179
Pertussis toxin **130**, 121
Photochemical reaction **130**, 11
Plasma insulin **130**, 171
Platelets **130**, 87
Polymorphonuclear leukocytes **130**, 29
Postprandial **130**, 161
Pravastatin **130**, 191
Procollagen type I **130**, 133
Proinsulin-like molecules **130**, 171
Proliferation **130**, 1, 45, 71
Prostaglandin E_1 **130**, 11

PTCA **130**, 113
Pulse-chase **130**, 143

Rat carotid artery **130**, 29
Release **130**, 87
Restenosis **130**, 29, 45, 71, 113
Retina **130**, 101

Sandoz-58035 **130**, 143
Serotonin **130**, 87
Serum triglycerides **130**, 171
Sex hormones **130**, 37, 183
Smoking **130**, 109
Smooth muscle cell **130**, 1, 71
Smooth muscle cells **130**, 45

Testosterone **130**, 37, 199
Total cholesterol **130**, 179
Tranilast **130**, 113
Triglyceride **130**, 93, 161
Triglycerides **130**, 143

Urate **130**, 223

Vascular risk factors **130**, 183
Vascular smooth muscle cells **130**, 61

Wolman disease **130**, 215